EVK-001: Completed Phase III enrollment

Evoke completed enrollment of about 200 female patients in a double-blind, placebo-controlled, U.S. Phase III trial evaluating 10 mg intranasal EVK-001 metoclopramide given 4 times daily for 4 weeks. ...